All-Cause Mortality and Progression Risks to Hepatic Decompensation and Hepatocellular Carcinoma in Patients Infected With Hepatitis C Virus-Reference-Cited by-同舟云学术

All-Cause Mortality and Progression Risks to Hepatic Decompensation and Hepatocellular Carcinoma in Patients Infected With Hepatitis C Virus

Published:2015-09-28 Issue:3 Volume:62 Page:289-297
ISSN:1058-4838
Container-title:Clinical Infectious Diseases
language:en
Short-container-title:Clin Infect Dis.

Author:

Xu Fujie,Moorman Anne C.,Tong Xin,Gordon Stuart C.,Rupp Loralee B.,Lu Mei,Teshale Eyasu H.,Spradling Philip R.,Boscarino Joseph A.,Trinacty Connie M.,Schmidt Mark A.,Holmberg Scott D.

Funder

CDC Foundation

AbbVie, Gilead Sciences, and Janssen Pharmaceuticals, Inc

Genentech, a member of the Roche Group, and Vertex Pharmaceuticals

Bristol-Myers Squibb

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Microbiology (medical)

Link

http://academic.oup.com/cid/article-pdf/62/3/289/16789324/civ860.pdf

Reference25 articles.

1. Care of the Cirrhotic Patient

2. Aging of Hepatitis C Virus (HCV)-Infected Persons in the United States: A Multiple Cohort Model of HCV Prevalence and Disease Progression

3. The Increasing Burden of Mortality From Viral Hepatitis in the United States Between 1999 and 2007

4. Causes of Death and Characteristics of Decedents With Viral Hepatitis, United States, 2010

5. American Association for the Study of Liver Diseases/Infectious Diseases Society of America /International AIDS Society–USA. When and in whom to initiate HCV therapy, 2014. Available at: http://www.hcvguidelines.org/node/91 . Accessed 5 April 2015.

Cited by 56 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Urinary caffeine and its metabolites in association with advanced liver fibrosis and liver steatosis: a nationwide cross-sectional study;Food & Function;2024

2. Hepatitis Flares or Hepatic Decompensation after Discontinuation of Tenofovir Disoproxil Fumarate and Entecavir in Non-Cirrhotic Hepatitis B e Antigen-Negative Patients;Journal of Clinical Medicine;2023-12-08

3. Real-World Effectiveness of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve, Compensated Cirrhotic HCV Patients;Infectious Diseases and Therapy;2023-06-17

4. The efficacy and markers of recurrence of stereotactic body radiation therapy alone for hepatocellular carcinoma with the portal vein invasion (≤5 cm);2023-05-30

5. Host Versus Virus: The Genetics in HCV Infection Leading to Treatment;Hepatitis C - Recent Advances;2023-02-17